BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Four Biopharma Companies Aim for Big Milestones in 2022

  Biopharma companies are building momentum to carry them through the bulk of 2022. BioSpace takes a look at some of the recent announcements.

  January 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  AN2 Therapeutics Nets $80 million for Novel Lung Disease Program

  California-based AN2 Therapeutics secured $80 million in a Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.

  January 7, 2022

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Drug Development

  Tonix is Tackling the Complexity of CNS and Pain Therapeutics

  Over the past ten years, Tonix’s pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.

  January 7, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Drug Development

  J&J Touts Real-World Vaccine Data; U.S. Likely to Miss WHO Vaccination Target

  As the Omicron strain sweeps the world, researchers rush to determine how effective vaccines are at creating immunity against the variant. For that and more, continue reading.

  January 7, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Policy

  Judge: FDA Cannot Have Until 2076 to Disclose Pfizer/BioNTech Vaccine Data

  Judge Mark Pittman found that the Freedom of Information Act filed by PHMPT is of paramount public importance and demands that the FDA make the data publicly available within eight months.

  January 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  AstraZeneca Doubles Down on ATTR-CM with Neurimmune Licensing Deal

  On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.

  January 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-Up: January 3-7

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

  January 7, 2022

   · 

  10 min read

   · 

  Mark Terry
• 

  Pharm Country

  Penn Scientists Combine CAR T and mRNA to Treat Cardiac Fibrosis

  Scientists from the University of Pennsylvania developed a new approach to address fibrosis, a leading cause of heart disease.

  January 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  John Maraganore is Embracing the Role of Biotech’s Newest Grandfather

  He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.

  January 7, 2022

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Business

  Sanofi Jumps on Early 2022 AI Train with Exscentia Deal

  Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.

  January 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN